More on fetal stem cells in treatment

First, a correction. The Forbes article concerning the treatment of Huntington's disease does have this line:

The procedure replaces striatal neurons lost to the debilitating illness with striatal neuroblasts and neural precursors obtained from embryos. These transplants grow to form mature replacement cells.

I assume that I made a mistake.

There is an earlier, 2000, report about the trial which I believe is available by free registration at Lancet.
From that report:

Five patients with Huntington's disease, identified genetically and clinically, were selected and gave informed consent to participate in a protocol which had received ethical approval from the French National Ethics Committee.

Neurosurgical procedures have been described previously. Whole ganglionic eminences were retrieved from 7·5–9·0-week-old fetuses and transplanted as small blocks. Two grafting sessions were planned: the first on the right side of the brain, and the second on the left side 1 year later. Tissue from either one or two fetuses was prepared but, due to volume restriction, the amount of tissue implanted in each session was roughly similar—ie, equivalent to that trimmed from one fetus.

None of which is relevant to the 5 day old embryos that we normally think of as being the source of "embryonic stem cells" which are said to be harvested from "left over embryos that are going to die, anyway."
We could consider these transplants as ethically equal to the transplant of tissue from prisoners who are intentionally killed, as is reported to be common in China.